ST3GAL6
ST3 Beta-Galactoside Alpha-2,3-Sialyltransferase 6
Gene Information Card
| Symbol | ST3GAL6 |
|---|---|
| Full Name | ST3 beta-galactoside alpha-2,3-sialyltransferase 6 |
| Gene Type | protein-coding |
| Chromosomal Location | 3q12.1 |
| NCBI Gene ID | 146713 ncbi.nlm.nih.gov/gene/146713 |
| Ensembl ID | ENSG00000163827 |
| UniProt ID | Q9Y274 |
| OMIM ID | 610132 |
| HGNC ID | 10863 |
| Aliases | SIAT10, ST3GalVI |
Description
ST3GAL6 encodes a Golgi membrane protein that catalyzes the transfer of sialic acid from CMP-sialic acid to galactose-containing substrates via an alpha-2,3 linkage. This sialyltransferase is involved in the biosynthesis of sialyl-Lewis X and other sialylated glycoconjugates, playing roles in cell-cell adhesion, immune response, and cancer metastasis.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Colorectal Cancer | Altered sialylation of cell surface glycoproteins promotes tumor invasion and metastasis. | PMID: 25691885 |
| Pancreatic Cancer | Upregulation of ST3GAL6 enhances sialyl-Lewis X synthesis, facilitating hematogenous metastasis. | PMID: 24987072 |
| Acute Myeloid Leukemia | ST3GAL6 expression correlates with poor prognosis and may modulate leukemic cell adhesion. | PMID: 25982141 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Liver | 12.5 | Medium |
| Colon | 9.8 | Medium |
| Pancreas | 7.2 | Low |
| Lung | 6.1 | Low |
| Bone Marrow | 4.3 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HepG2 | 15.2 | Hepatocellular carcinoma cell line |
| SW480 | 11.0 | Colorectal adenocarcinoma cell line |
| PANC-1 | 8.5 | Pancreatic carcinoma cell line |
| A549 | 5.3 | Lung carcinoma cell line |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1045G>A (p.Gly349Arg) | Missense | <0.01% | Unknown functional effect |
| c.1237C>T (p.Arg413Cys) | Missense | <0.01% | Unknown functional effect |
Mutation functional classification
Loss of Function (LOF)
No confirmed loss-of-function mutations reported in ClinVar or COSMIC.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported.
Dominant Negative (DN)
No evidence for dominant-negative effects.
View complete mutation data：
Gene Ontology (GO)
| • sialyltransferase activity (GO:0008373) | • Golgi apparatus (GO:0005794) |
| • protein N-linked glycosylation via asparagine (GO:0016262) | • protein glycosylation (GO:0006486) |
| • Golgi membrane (GO:0000139) |
Pathways
• Glycosphingolipid biosynthesis - lacto and neolacto series (KEGG: hsa00601)
• Metabolism of carbohydrates (Reactome: R-HSA-71387)
• Sialic acid metabolism (Reactome: R-HSA-4085001)
Protein Summary
ST3GAL6 is a type II membrane protein localized to the Golgi apparatus. It contains a short N-terminal cytoplasmic domain, a transmembrane region, and a large C-terminal catalytic domain facing the Golgi lumen. The enzyme transfers sialic acid to terminal galactose residues on glycoproteins and glycolipids, forming alpha-2,3 linkages. Its activity is critical for the synthesis of sialyl-Lewis X, a ligand for selectins involved in leukocyte trafficking and cancer cell metastasis.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| ST3GAL6 Knockout HEK293 Cell Line | EDJ-KQ7036 | Human | 10402 | Details Get a Quote |
| ST3GAL6 Knockout A-549 Cell Line | EDJ-KQ31796 | Human | 10402 | Details Get a Quote |
| ST3GAL6 Knockout HCT 116 Cell Line | EDJ-KQ31797 | Human | 10402 | Details Get a Quote |
| ST3GAL6 Knockout HeLa Cell Line | EDJ-KQ55400 | Human | 10402 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
